HomeCompareAGE vs O

AGE vs O: Dividend Comparison 2026

AGE yields 18.02% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGE wins by $30.4K in total portfolio value
10 years
AGE
AGE
● Live price
18.02%
Share price
$11.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.6K
Annual income
$5,421.64
Full AGE calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — AGE vs O

📍 AGE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGEO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGE + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGE pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGE
Annual income on $10K today (after 15% tax)
$1,531.53/yr
After 10yr DRIP, annual income (after tax)
$4,608.39/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, AGE beats the other by $271.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGE + O for your $10,000?

AGE: 50%O: 50%
100% O50/50100% AGE
Portfolio after 10yr
$49.4K
Annual income
$5,262.19/yr
Blended yield
10.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

AGE
No analyst data
Altman Z
-20.5
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGE buys
0
O buys
0
No recent congressional trades found for AGE or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGEO
Forward yield18.02%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$64.6K$34.2K
Annual income after 10y$5,421.64$5,102.74
Total dividends collected$34.8K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: AGE vs O ($10,000, DRIP)

YearAGE PortfolioAGE Income/yrO PortfolioO Income/yrGap
1← crossover$12,502$1,801.80$10,818$608.16+$1.7KAGE
2$15,482$2,105.21$11,787$741.68+$3.7KAGE
3$19,002$2,436.52$12,946$911.00+$6.1KAGE
4$23,127$2,794.89$14,345$1,127.94+$8.8KAGE
5$27,925$3,179.07$16,056$1,409.05+$11.9KAGE
6$33,468$3,587.47$18,171$1,777.83+$15.3KAGE
7$39,829$4,018.19$20,820$2,268.21+$19.0KAGE
8$47,086$4,469.06$24,188$2,929.90+$22.9KAGE
9$55,319$4,937.71$28,533$3,837.11+$26.8KAGE
10$64,613$5,421.64$34,235$5,102.74+$30.4KAGE

AGE vs O: Complete Analysis 2026

AGEStock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Full AGE Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this AGE vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGE vs SCHDAGE vs JEPIAGE vs KOAGE vs MAINAGE vs STAGAGE vs ADCAGE vs NNNAGE vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.